Change in number of shares and votes in Alligator Bioscience
During the month of December, the number of shares and votes in Alligator Bioscience AB has changed due to conversion of a total of 170,681 ...
Alligator Bioscience AB announces outcome of exercise of warrants series TO 9
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...
Last day of trading in warrants series TO 9 in Alligator Bioscience AB is 13 December 2024
13 December 2024 is the last day of trading in warrants series TO 9 in Alligator Bioscience AB (“Alligator Bioscience” or the &# ...
Alligator Bioscience publishes financial calendar for 2025
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025: Extraordinary General ...
Alligator Announces First Patient Dosed in Shanghai Henlius Biotech, Inc. Phase 3 Clinical Trial
Lund, Sweden, November 27, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Company was notified that th ...
Alligator Bioscience resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program
The board of directors of Alligator Bioscience AB (“Alligator”) has on 3 December 2024 resolved to convert 170,681 series C shar ...
Exercise price determined for the exercise of warrants series TO 9 in Alligator Bioscience AB
Alligator Bioscience AB (“Alligator” or the “Company”) hereby announces that the exercise price for warrants series ...
Notice of extraordinary general meeting in Alligator Bioscience AB
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...
Alligator sharpens focus on mitazalimab and announces cost reduction program to maximize long-term value creation
Sharpening focus on preparing mitazalimab for Phase 3 and continuing partnering discussions Planned reduction of workforce, mainly wit ...